Summary
Infringement and essentiality of a telecommunications patent must be assessed claim by claim and by reference to the patent’s proper construction. Added matter and infringement by equivalence involve distinct legal tests. A strict novelty-type disclosure test applies to added matter; prosecution amendments do not prevent an equivalent from falling within the amended claim where the ordinary Actavis questions are satisfied.
For Crown use, a written authorisation to perform an identified act is sufficient even if it does not identify the patent and infringement is not necessary to perform the authorised act. The statutory examples of services of the Crown are non-exhaustive. Rare use of patented emergency-access technology is not necessarily de minimis, particularly where maintaining readiness is commercially significant.
Factual background
IPcom GmbH & Co Kg alleged that Vodafone’s 4G network systems infringed EP(UK) 2,579,666. The patent concerned access control for a telecommunications channel using privileged-user bypass access and a random threshold lottery.
The court considered construction of unconditional and conditional amended claims, added matter, extension of protection, obviousness over GSM/GPRS and IS-95, essentiality to an LTE standard, direct and indirect infringement, Crown use, de minimis, and declarations of non-infringement. The central issues included whether the amended claims were allowable, whether the LTE access-control option was essential, and whether Vodafone’s emergency-access and network activities were protected by statutory defences.
Held
- Construction and validity. “Access right” included an allocation which resulted in either access or denial following the lottery. Claim 1 identified three routes through the claim, and privileged and normally privileged users were mutually exclusive classes for the claim’s operation. The claims required access-class bits for privileged classes, not every user class. “Set up to send” meant appropriately programmed, adapted or configured to send the relevant signals.
- The unconditional claim 1 disclosed a single combined check, whereas the application disclosed only a two-stage check. It therefore contained added matter and was invalid, together with claims dependent on it. The conditional claim 1 was allowable. The remaining added-matter attacks and the objection based on extension of protection failed.
- Obviousness. Vodafone’s combination of GSM/GPRS and IS-95 required a succession of choices. Even if earlier steps were obvious, the later sequence was unrealistic and hindsight-driven. Neither prior-art system disclosed or suggested the claimed lottery-bypass mechanism. The obviousness attack failed.
- Essentiality and infringement. Where the LTE access-control option in 3GPP TS 36.331 was implemented, conditional claim 1 and unconditional claim 13 were essential. Conditional claim 1 was not infringed on its ordinary construction because the standard used one check, but it was infringed under the doctrine of equivalents. The amended claim did not make strict compliance with two checks essential. Claims concerning systems requiring only power to operate the access-control function could be infringed; systems requiring additional programming were not “set up to send”.
- Crown use and de minimis. The statutory examples in section 56(2) were non-exhaustive. A written authorisation identifying the relevant act established Crown use even without identifying the patent or proving that infringement was necessary. The MTPAS emergency-access scheme, including reasonable testing and keeping equipment ready to respond, fell within the defence. The rare nature of the use did not make the relevant acts de minimis.
- Indirect infringement and declarations. The supply of SIM cards did not satisfy the knowledge and intention requirements of section 60(2). Vodafone’s applications for declarations that the Alpha, Beta and Gamma base stations did not infringe succeeded, subject to limitation to LTE/4G operation. Certain Group 1 methods infringed, subject to the Crown-use defence for MTPAS; Group 2 apparatus did not infringe.
The court’s approach to earlier authorities
Available to signed-in members.
Appellate history
The court recorded that an earlier application to adjourn the expedited trial and amend the case had been refused: [2019] EWHC 3323 (Pat). The present judgment was a first-instance determination of the infringement trial.
Appeal route
- This judgment [2020] EWHC 132 (Pat) High Court (Patents Court)
- Appealed to[2021] EWCA Civ 205Outcomeipcom appeal allowed in part; vodafone appeal dismissed
Key cases cited
The 30 most senior of 37 authorities cited.
- Actavis Group PTC EHF and others v ICOS Corporation and another [2019] UKSC 15
- Actavis UK Ltd v Eli Lilly & Co [2017] UKSC 48
- Sienkiewicz (Administratrix of the Estate of Enid Costello Deceased) v Greif (UK) Limited [2011] UKSC 10
- Icescape Ltd v Ice-World International BV & Ors [2018] EWCA Civ 2219
- AP Racing Ltd v Alcon Components Ltd [2014] EWCA Civ 40
- Nokia OYJ (Nokia Corporation) v IPCom GmbH & Co Kg [2012] EWCA Civ 567
- Grimme Maschinenfabrik GmbH & Co KG v Scott (t/a Scotts Potato Machinery) [2010] EWCA Civ 1110
- Napp Pharmaceutical Holdings Ltd v Ratiopharm GmbH [2009] EWCA Civ 252
- Vector Corporation v Glatt Air Techniques Inc [2007] EWCA Civ 805
- Nokia Corporation v Interdigital Technology Corporation [2005] EWCA Civ 614
- Technip France SA’s Patent [2004] RPC 46
- Conversant Wireless Licensing SARL v Huawei Technologies Co., Ltd & Ors [2019] EWHC 1687 (Pat)
- Allergan, Inc & Anor v Aspire Pharma Ltd [2019] EWHC 1085 (Pat)
- Fujifilm Kyowa Kirin Biologics Company Ltd v Abbvie Biotechnology Ltd (Rev 1) [2017] EWHC 395 (Pat)
- NAPP Pharmaceutical Holdings Ltd v Dr Reddy's Laboratories (UK) Ltd & Anor [2016] EWHC 1517 (Pat)
- IPCOM GmbH & Co Kg v HTC Europe Co Ltd & Ors [2015] EWHC 1034 (Pat)
- Hospira UK Ltd v Genentech Inc [2014] EWHC 3857 (Pat)
- Koninklijke Philips Electronics NV v Nintendo of Europe GmbH [2014] EWHC 1959 (Pat)
- Rovi Solutions Corporation & Anor v Virgin Media Ltd & Ors [2014] EWHC 1559 (Pat)
- Nestec SA & Ors v Dualit Ltd & Ors [2013] EWHC 923 (Pat)
- Nokia Oyj (Nokia Corporation) v IPCom GmbH & Co Kg [2011] EWHC 1470 (Pat)
- Gedeon Richter Plc v Bayer Schering Pharma AG [2011] EWHC 583 (Pat)
- Nokia GmbH v Ipcom GmbH & Co KG [2009] EWHC 3482 (Pat)
- MMI Research v Cellxion [2009] EWHC 1533 (Pat)
- Ratiopharm GMBH v NAPP Pharmaceutical Holdings Ltd [2008] EWHC 3070 (Pat)
- Qualcomm Incorporated (A Delaware Corporation) v Nokia Corporation (A Finnish Company) [2008] EWHC 329 (Pat)
- Nokia Corp v Interdigital Technology Corp [2007] EWHC 3077 (Pat)
- Monsanto Technology LLC v Cargill International SA & Anor [2007] EWHC 2257 (Pat)
- Henry Brothers (Magherafelt) Ltd v Ministry of Defence [1999] RPC 442
- Hoechst Celanese Corporation v BP Chemicals Ltd [1998] FSR 586
Sign in to see how the court treated each authority and the other 7. A free account is enough.
Cases citing this case
1 later case · 1 neutral
Most senior citing decisions:
- Evalve Inc & Ors Edwards Lifesciences Ltd [2020] EWHC 513 (Pat) mentioned
Sign in for the full treatment table. A free account is enough.